Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Current Assets (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Current Assets for 4 consecutive years, with $485.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 13.73% to $485.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $485.1 million, a 13.73% decrease, with the full-year FY2025 number at $485.1 million, down 13.73% from a year prior.
  • Current Assets was $485.1 million for Q4 2025 at Day One Biopharmaceuticals, down from $490.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $581.0 million in Q3 2024 to a low of $326.0 million in Q1 2024.
  • A 4-year average of $451.4 million and a median of $467.4 million in 2023 define the central range for Current Assets.
  • Biggest YoY gain for Current Assets was 56.01% in 2025; the steepest drop was 15.67% in 2025.
  • Day One Biopharmaceuticals' Current Assets stood at $347.9 million in 2022, then increased by 7.88% to $375.3 million in 2023, then surged by 49.85% to $562.3 million in 2024, then fell by 13.73% to $485.1 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Current Assets are $485.1 million (Q4 2025), $490.0 million (Q3 2025), and $494.4 million (Q2 2025).